In a 37‑year‑old patient with BMI 32.1, blood pressure 140/88 mmHg, taking atorvastatin 20 mg and Dovato (dolutegravir 50 mg/lamivudine 300 mg), and labs showing total cholesterol 150 mg/dL, LDL 78 mg/dL, HDL 33 mg/dL (low), triglycerides 289 mg/dL (high), and hemoglobin A1c 5.0 %, what is the optimal management for his elevated triglycerides, low HDL, overweight/obesity, and borderline hypertension?

Management of Hypertriglyceridemia, Low HDL, Obesity, and Borderline Hypertension in a 37-Year-Old on HIV Therapy

Intensify your patient's atorvastatin from 20 mg to 40-80 mg daily to address the moderate hypertriglyceridemia (289 mg/dL) and low HDL (33 mg/dL), while simultaneously implementing aggressive lifestyle modification targeting weight loss of 5-10% through a structured program like the Diabetes Prevention Program, and initiate blood pressure monitoring with consideration for antihypertensive therapy if BP remains ≥140/90 mmHg on repeat measurements.

Lipid Management: Statin Intensification

Your patient has moderate hypertriglyceridemia (289 mg/dL, which falls in the 175-499 mg/dL range) combined with critically low HDL cholesterol (33 mg/dL, well below the goal of ≥40 mg/dL). According to the 2018 ACC/AHA cholesterol guidelines, you should address lifestyle factors, obesity, and metabolic syndrome first, but also consider intensifying statin therapy given the persistent dyslipidemia 1.

Why Increase Atorvastatin Dose:

• Atorvastatin is uniquely effective for hypertriglyceridemia among statins. At 20 mg, it reduces triglycerides by approximately 32%, but at 80 mg, this increases to 46% reduction 2. The dose-response is substantial and clinically meaningful.

• Atorvastatin addresses multiple atherogenic lipid abnormalities beyond LDL. It significantly reduces VLDL cholesterol (the triglyceride-rich lipoprotein), small dense LDL particles, and remnant lipoproteins—all elevated in hypertriglyceridemia 3. At 80 mg, VLDL-C reductions reach 58% compared to 34% at 5 mg 2.

• The patient's LDL is already at 78 mg/dL (well-controlled), so you have room to intensify therapy without concern about over-treatment. The primary target here is the triglycerides and the atherogenic dyslipidemia pattern.

Important Caveat About Dolutegravir:

Dolutegravir (in Dovato) is contributing to this dyslipidemia. Recent prospective data show that DTG-based regimens cause significant adverse lipid changes over 12 months: triglycerides increase by ~23 mg/dL, LDL rises by ~15 mg/dL, and HDL tends to decline 4. The incidence of new dyslipidemia on DTG reaches 34% at one year, with 71% of those affected having multiple lipid abnormalities 4. However, do not discontinue Dovato—it's providing excellent HIV control (evidenced by stable therapy). Instead, treat through the dyslipidemia with intensified statin therapy.

Dosing Recommendation:

• Start with atorvastatin 40 mg daily (doubling current dose). Recheck lipids in 6-8 weeks.
• If triglycerides remain >200 mg/dL, advance to 80 mg daily. This dose provides maximal triglyceride reduction (46%) and addresses the full atherogenic lipid profile 2, 3.
• Monitor ALT at follow-up, as atorvastatin can elevate liver enzymes, and DTG itself raises ALT (mean increase 12.6 IU/L) 4. However, this is usually not clinically significant unless ALT exceeds 3× upper limit of normal.

Weight Management: Structured Behavioral Program

With BMI 32.1 (Class I obesity) and metabolic syndrome features (hypertriglyceridemia, low HDL, borderline hypertension), weight loss of 5-10% (approximately 10-20 lbs for this patient) will significantly improve all metabolic parameters 5.

Specific Program Recommendation:

Enroll in the Diabetes Prevention Program (DPP) or similar structured program 5:

• 16-session curriculum over 6 months with lifestyle coach
• Self-monitoring of weight weekly
• Food tracking with calorie goals (typically 1,200-1,800 kcal/day depending on baseline)
• ≥150 minutes/week of moderate physical activity
• Evidence shows 2.3 kg (5 lb) mean weight loss, but more importantly, decreases in blood pressure, lipids, and inflammatory markers 5
• Covered by Medicare for eligible patients; check commercial insurance coverage

Dietary Approach:

Mediterranean diet is optimal for this patient's lipid profile 5:

• Decreases triglycerides, LDL-C, and blood pressure
• Increases HDL-C (critical for your patient with HDL of 33 mg/dL)
• Focus on dark green vegetables, fruits, nuts, legumes, fish/seafood
• Extra virgin olive oil as main fat source
• Low intake of red meat and dairy fat

Alternative: Low-carbohydrate diet (<40% calories from carbs) specifically targets triglycerides and raises HDL 5. This may be more effective for hypertriglyceridemia than Mediterranean diet (6.4% vs 2.5% weight loss), with documented decreases in triglycerides and increases in HDL-C 5.

Blood Pressure Management

BP of 140/88 mmHg meets the threshold for Stage 2 hypertension (systolic ≥140). However, confirm with repeat measurements before initiating pharmacotherapy:

• Obtain 2-3 additional BP readings over 1-2 weeks
• Consider home BP monitoring or 24-hour ambulatory monitoring
• If confirmed ≥140/90 mmHg, initiate antihypertensive therapy

First-line agent: ACE inhibitor or ARB (e.g., lisinopril 10 mg daily or losartan 50 mg daily):

• Provides cardiovascular and renal protection
• No significant drug interactions with Dovato 6
• Particularly beneficial given obesity and metabolic syndrome

Monitoring Plan

6-8 week follow-up:

• Fasting lipid panel (assess triglyceride and HDL response to intensified statin)
• ALT, AST (monitor for statin-related hepatotoxicity, especially with concurrent DTG)
• Creatinine (DTG increases creatinine by ~0.11 mg/dL through inhibition of tubular secretion, not true renal dysfunction) 4
• Weight and BP
• Assess adherence to dietary changes and physical activity

3-6 month follow-up:

• Repeat lipid panel
• Hemoglobin A1c (currently 5.0%, excellent, but monitor given obesity and metabolic syndrome)
• If triglycerides remain >200 mg/dL despite atorvastatin 80 mg and lifestyle modification, consider adding icosapent ethyl (Vascepa) 2 grams twice daily or omega-3 fatty acids 1

What NOT to Do

Do not add fibrate therapy at this time. While fibrates (gemfibrozil, fenofibrate) are effective for hypertriglyceridemia, they:

• Increase risk of myopathy when combined with statins
• May have reduced efficacy when combined with protease inhibitors (though Dovato contains integrase inhibitor, not protease inhibitor, this concern is less relevant) 7
• Should be reserved for severe hypertriglyceridemia (≥500 mg/dL) or failure of maximized statin therapy 1

Do not switch from Dovato. While DTG contributes to dyslipidemia, the HIV virologic control is paramount. Treat through the metabolic side effects rather than compromising HIV therapy 4.

Do not use simvastatin or lovastatin if you ever consider switching statins—these are extensively metabolized by CYP3A4 and have significant drug interaction potential, though less relevant with integrase inhibitors than protease inhibitors 7.